RECRUITINGINTERVENTIONAL
Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients
About This Trial
The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
- patients with burn percentage of 25% to 50% of total body surface area
- patients with second to third degree burns
- ASA 1 and ASA 2 patients
Who Should NOT Join This Trial:
- Burn percentage more than 50% or less than 25% of total body surface area
- Having autoimmune conditions (where your immune system attacks your own body)s
- Cancer patients
- ASA 3 and ASA 4 patients
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
* patients with burn percentage of 25% to 50% of total body surface area
* patients with second to third degree burns
* ASA 1 and ASA 2 patients
Exclusion Criteria:
* Burn percentage more than 50% or less than 25% of total body surface area
* Having autoimmune diseases
* Cancer patients
* ASA 3 and ASA 4 patients
Treatments Being Tested
DIAGNOSTIC_TEST
Interleukin 6
Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
Locations (1)
Ain Shams University
Cairo, Egypt